Want to see BMEA full AI Analyst Report?
Top Page
Biomea Fusion
(NASDAQ:BMEA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-20.00% Downside)
Action:Reiterated
Date:08/06/26
The score is primarily held down by weak financial performance (no revenue, ongoing losses and cash burn, shrinking equity base) and bearish/soft technical signals (below longer-term moving averages and negative MACD). Valuation is hard to assess due to negative earnings and no dividend, while the recent governance-related shareholder dissent adds incremental risk.
Positive Factors
Proprietary covalent drug discovery platform
Biomea’s proprietary covalent chemistry approach is a durable scientific differentiator. It enables selective, potentially longer‑lasting inhibition of disease drivers, supporting a defensible R&D engine that can produce multiple distinct small‑molecule candidates in oncology and metabolic disease over time.
Negative Factors
No revenue; persistent negative free cash flow
As a clinical‑stage biotech with no product sales, ongoing negative FCF requires external financing to sustain operations. A persistent ~-$47M TTM burn rate means runway and dilution risk are structural until partnerships, milestones, or approvals produce recurring cash inflows.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary covalent drug discovery platform
Biomea’s proprietary covalent chemistry approach is a durable scientific differentiator. It enables selective, potentially longer‑lasting inhibition of disease drivers, supporting a defensible R&D engine that can produce multiple distinct small‑molecule candidates in oncology and metabolic disease over time.
Read all positive factors
Biomea Fusion (BMEA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$97.85M
Dividend YieldN/A
Average Volume (3M)2.40M
Price to Earnings (P/E)―
Beta (1Y)1.86
Revenue GrowthN/A
EPS Growth83.55%
CountryUS
Employees40
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.50
Shares Outstanding72,483,850
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.80Price Target Upside444.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Biomea Fusion Business Overview & Revenue Model
Company Description
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various...
How the Company Makes Money
Biomea Fusion is a clinical-stage biotechnology company, and detailed, consistent operating revenue streams from product sales are not publicly evident because it does not have approved, commercialized drugs. As a result, the company’s ability to ...
Biomea Fusion Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -93.00K | -1.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -34.21M | -60.39M | -136.68M | -115.74M | -81.14M | -41.32M |
| Net Income | -32.54M | -61.80M | -138.43M | -117.25M | -81.83M | -41.57M |
Balance Sheet | ||||||
| Total Assets | 36.87M | 58.57M | 79.94M | 199.93M | 129.31M | 185.71M |
| Cash, Cash Equivalents and Short-Term Investments | 34.82M | 55.81M | 58.28M | 176.87M | 113.05M | 173.52M |
| Total Debt | 877.00K | 1.59M | 8.77M | 10.30M | 2.29M | 2.85M |
| Total Liabilities | 24.74M | 29.02M | 28.36M | 30.69M | 20.77M | 6.92M |
| Stockholders Equity | 12.14M | 29.55M | 51.57M | 169.24M | 108.54M | 178.78M |
Cash Flow | ||||||
| Free Cash Flow | -47.06M | -70.37M | -120.26M | -99.96M | -63.45M | -38.61M |
| Operating Cash Flow | -47.06M | -70.37M | -119.89M | -96.59M | -62.42M | -35.44M |
| Investing Cash Flow | 550.00K | 0.00 | -362.00K | -2.22M | 27.34M | -33.35M |
| Financing Cash Flow | 25.11M | 67.90M | 1.67M | 163.80M | 1.24M | 153.19M |
Biomea Fusion Technical Analysis
Positive
1.25
Price Trends
1.27
Positive
1.42
Negative
1.35
Negative
Market Momentum
<0.01
Negative
61.05
Neutral
80.19
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMEA, the sentiment is Positive. The current price of 1.25 is below the 20-day moving average (MA) of 1.26, below the 50-day MA of 1.27, and below the 200-day MA of 1.35, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.05 is Neutral, neither overbought nor oversold. The STOCH value of 80.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BMEA.
Biomea Fusion Risk Analysis
Biomea Fusion disclosed 91 risk factors in its most recent earnings report. Biomea Fusion reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biomea Fusion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $321.90M | 2.63 | -38.12% | ― | 30.47% | ― | |
53 Neutral | $564.41M | -8.03 | -23.64% | ― | -76.20% | 52.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $118.91M | -0.99 | -6.14% | ― | -100.00% | 54.89% | |
47 Neutral | $112.41M | -1.66 | -26.58% | ― | -13.23% | 12.29% | |
44 Neutral | $97.85M | -2.72 | -171.19% | ― | ― | 83.55% | |
43 Neutral | $27.84M | -0.64 | -84.91% | ― | ― | -28.83% |
* Healthcare Sector Average
BMEA
Biomea Fusion
1.35
-0.37
-21.51%
AGEN
Agenus
7.53
3.00
66.23%
INO
Inovio Pharmaceuticals
1.20
-0.74
-38.14%
ATOS
Atossa Therapeutics
2.59
-8.66
-76.98%
OVID
Ovid Therapeutics
2.84
1.90
202.13%
SEER
Seer
2.02
-0.02
-0.98%
Biomea Fusion Corporate Events
Executive/Board ChangesShareholder Meetings
Biomea Fusion Shareholders Reject Director Nominees, Ratify Auditor
Negative
Jun 11, 2026
At the Annual Meeting of Stockholders held on June 10, 2026, Biomea Fusion shareholders voted on director elections and auditor ratification, with 43,924,456 of the 72,299,440 eligible common shares present or represented by proxy. The two Class I...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.